Results 91 to 100 of about 6,967 (165)

Tolvaptan for treatment of iatrogenic hyponatremia [PDF]

Journal of Neuroanaesthesiology and Critical Care, 2016
openaire   +3 more sources

The prospect of novel orphan therapeutic protocol for TSC2/PKD1 contiguous gene syndrome: a case report. [PDF]

BMC Nephrol
Agavriloaei BD, Costache RC, Babici RG, Racoviță S, Dodi G, Covic AC, Mititiuc IL.   +6 more
europepmc   +1 more source

A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials

Journal of Nephrology
I. Kitty Stanley, Anton M. Palma, Andrea K. Viecelli, David W. Johnson, Carmel M. Hawley, Christine E. Staatz, Andrew J. Mallett   +6 more
openaire   +2 more sources

Safety and efficacy of tolvaptan in real‑world Japanese patients with autosomal dominant polycystic kidney disease: final results of SLOW‑PKD surveillance. [PDF]

Clin Exp Nephrol
Mochizuki T, Muto S, Suzue K, Komaniwa S, Tanaka T, Fukuta Y, Yamashige Y.   +6 more
europepmc   +1 more source

Tolvaptan for the Treatment of Elephantiasis Nostras Verrucosa

Internal Medicine, 2019
Yuko Eda, Shinji Hasegawa, Nobuyuki Ogasawara, Yoh Arita   +3 more
openaire   +4 more sources

Recurrent hyponatremia due to syndrome of inappropriate antidiuresis after traumatic brain injury: two case reports. [PDF]

Front Endocrinol (Lausanne)
Petria I, Indirli R, Mantovani B, Lanzi V, Mantovani G, Ferrante E.   +5 more
europepmc   +1 more source

Sindrome iponatriemica [PDF]

, 2012
CAIMI, Gregorio, URSO, Caterina
core  

Importance of early use of tolvaptan in hyponatremic acutely decompensated heart failure patients, a retrospective study. [PDF]

Egypt Heart J
Soerarso R, Yonas E, Sirait SP, Hasanah DY, Raharjo SB, Siswanto BB, Cramer MJ, van der Harst P, Oerlemans MIFJ.   +8 more
europepmc   +1 more source

Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model. [PDF]

PLoS One
Oronel LH, Ortiz M, Yarza C, Gayone S, Davio C, Majowicz M, Albertoni Borghese MF.   +6 more
europepmc   +1 more source

Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities. [PDF]

Toxicol Sci
Hammond S, Meng X, Barber J, Mosedale M, Chadwick A, Watkins PB, Naisbitt DJ.   +6 more
europepmc   +1 more source